These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16978694)

  • 1. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszyńska A; Roliński J
    Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
    Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
    Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
    Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
    Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
    Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
    Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
    Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 10. Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
    Ayyildiz O; Isikdogan A; Bolaman Z; Muftuoglu E
    Saudi Med J; 2004 Dec; 25(12):2054-6. PubMed ID: 15711709
    [No Abstract]   [Full Text] [Related]  

  • 11. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
    Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
    Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
    Hussein MA; Gundacker H; Head DR; Elias L; Foon KA; Boldt DH; Dobin SM; Dakhil SR; Budd GT; Appelbaum FR
    Leukemia; 2005 Nov; 19(11):1880-6. PubMed ID: 16193091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
    Schierl M; Foedinger D; Geissler K; Rappersberger K; Feldmann R
    Eur J Dermatol; 2008; 18(6):717-8. PubMed ID: 19049939
    [No Abstract]   [Full Text] [Related]  

  • 15. A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
    Haines I; Elliott P; Stanley R
    Intern Med J; 2009 Apr; 39(4):269-71. PubMed ID: 19402870
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fludarabine treatment of chronic lymphoid leukemia].
    Gabeeva NG; Pivnik AV; Moiseeva TN; Zybunova EE; Samoĭlova RS; Kremenetskaia AM; Varlamova EIu; Kaplanskaia IB
    Ter Arkh; 2000; 72(8):42-5. PubMed ID: 11019427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
    Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
    Giles FJ; Shi GG; Cortes JE; Thomas D; Keating AR; Kantarjian HM; Keating MJ; O'Brien SM
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):223-8. PubMed ID: 12783199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.